ClotPro: New Innovative Thromboelastometer

Novel Innovative Analyzer for Viscoelastometry

– A unique combination of ease of use, flexibility, and throughput –

Major Features

Ease of use

  • Reagent handling eliminated with the Active Tip™ Technology
  • Intuitive interface
  • Screen sharing for live-view of active tests in remote locations
  • Forwarding of test results by e-mail or app
  • Consistent test procedure across test menu

Efficiency

  • 6-channel system for maximum throughput and flexibility
  • Small blood volume needed: can be used for paediatric blood samples
  • Fast time-to-result: first results in 3 minutes

Powerful assay menu

  • Differentiation of blood coagulation via extrinsic and intrinsic assays
  • Specific tests for DOACs and antifibrinolytics

Seamless adoption

  • Excellent correlation to other instruments on the market
  • Use of established parameters

The ClotPro Instrument

The ClotPro instrument is a 6 channel viscoelastometry analyzer, designed for the rapid analysis of whole blood coagulation. The ClotPro allows you to analyse up to 6 assays simultaneously in any test combination. Tests can be repeated after therapeutic interventions as required and the diagnostic workup can be developed step by step. For this, the ClotPro instrument has the highest throughput and flexibility, efficient and easy to use.

Active Tip™ Technology

The Active Tip technology is designed to eliminate reagent handling on the ClotPro analyzer. The reagents are present in a little sponge in the pipetting tip in dry form. During pipetting of the blood sample the reagents are transferred into the blood – simple and safe.

Applications

ClotPro enables the detection and assessment of factor deficiencies, low fibrinogen, platelet contribution (to whole blood coagulation), heparin and DOAC effects, fibrinolysis and antifibrinolytic drugs.

The benefits of viscoelastic coagulation monitoring have been described in many fields of surgery and intensive care: Cardiac and vascular surgery, organ transplantation, trauma, obstetrics, orthopaedic surgery and intensive care.

ClotPro reagents for screening of DOACs in whole blood -

The established screening assays

EX-test

Assessment of the extrinsic coagulation pathway 

Ready to use system reagent for the assessment of the extrinsic coagulation pathway and its interaction with blood platelets in citrated blood on the ClotPro system. In EX-test CaCl2 recalcifies the sample and recombinant tissue factor activates coagulation. Hexadimethrine bromide is added to the reagent to antagonize any heparin that may be present in the sample. 

FIB-test

Functional detection of the fibrinogen level

Ready to use system reagent for examination of the fibrinogen level and fibrin polymerization in citrated blood on the ClotPro system. In FIB-test CaCl2 recalcifies the sample and recombinant tissue factor activates the extrinsic coagulation pathway. Platelets are inhibited by dual inhibition with cytochalasin D and a synthetic GP2b3a antagonist. Hexadimethrine bromide is added to the reagent to antagonize any heparin that may be present in the sample.

IN-test

Assessment of the intrinsic coagulation pathway

Ready to use system reagent for the assessment of the intrinsic coagulation pathway and its interaction with blood platelets in citrated blood on the ClotPro system. Assessment of heparin, sensitive to FVIII. CaCl2 recalcifies the sample and ellagic acid activates coagulation.

HI-test

IN-test with heparin inhibition

Ready to use system reagent for heparin insensitive assessment of the intrinsic coagulation pathway and its interaction with blood platelets in citrated blood on the ClotPro system. HI-test neutralizes heparin in-vitro with heparinase. CaCl2 recalcifies the sample and ellagic acid activates coagulation.

AP-test

Assessment of coagulation using fibrinolysis inhibition

Ready to use system reagent for the fibrinolysis-independent assessment of the extrinsic coagulation pathway and its interaction with blood platelets in citrated blood on the ClotPro system. In AP-test fibrinolysis is inhibited in-vitro using aprotinin, a potent direct antagonist of plasmin, the effector protease of fibrinolysis. CaCl2 recalcifies the sample and recombinant tissue factor activates coagulation. Hexadimethrine bromide is added to the reagent to antagonize heparin that may be present in the sample.

New assays for drug monitoring

NA-test

Non activated test

Ready to use system reagent for the detection of non-activated coagulation in citrated blood on the ClotPro system. CaCl2 recalcifies the sample.

RVV-test

Highly sensitive to direct oral anticoagulants (DOACs)

Ready to use system reagent for the detection of factor Xa (FXa) and Factor IIa (FXa) antagonists in citrated blood on the ClotPro system. CaCl2 recalcifies the sample and reagent derived from Russells viper venom (RVV) activates FX in the sample to FXa. This FXa triggers coagulation and clot formation.

ECA-test

Highly sensitive to Anti-IIa DOACs and direct Thrombin antagonists

Ready to use system reagent for the detection of Factor IIa antagonists, such as Dabigatran, in citrated blood for the ClotPro analyzer. Ecarin, a prothrombin (Factor II) activator derived from the venom of the saw-scaled viper (Echis carinatus) which leads to activated thrombin (Factor IIa) in the blood sample. Polybrene is added to the reagent to antagonize heparin that may be present in the sample.

TPA-test

Assessment of coagulation with fibrinolysis activation

Ready to use system reagent for the detection of antifibrinolytic agents, such as Tranexamic acid (TXA), in citrated blood on the ClotPro system. Fibrinolysis is triggered in vitro using recombinant tissue plasminogen activator (r-tPA), a potent activator of plasmin.

Tip

 for Rapid DOAC screening

The RVV-test is a rapid screening test that uses a direct activation of Factor X. It has a high sensitivity to all direct oral anticoagulants and thrombin antagonists. The ECA-test makes use of a direct activation of prothrombin, andhas a high sensitivity and specificity for thrombin antagonists only. The combination of these two test allows for a rapid detection and differentiation between anti-FXa and thrombin antagonists in urgent situations.